The Use of Erythropoiesis-Stimulating Agents in the Intensive Care Unit

Critical Care Clinics

Volumn 28, Issue 3, 2012, Pages 345-362

  Piagnerelli, Michael ^a   Vincent, Jean Louis ^b  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b ERASME HOSPITAL   (Belgium)

Author keywords

Anemia; Erythropoietin; Iron; Transfusion

Indexed keywords

ANTIANEMIC AGENT; ERYTHROPOIETIN; FERRITIN; HEMOGLOBIN; HEPCIDIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; IRON; IRON REGULATORY PROTEIN 1; IRON REGULATORY PROTEIN 2; JANUS KINASE 2; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; REACTIVE OXYGEN METABOLITE; RECOMBINANT ERYTHROPOIETIN; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR ALPHA;

ANEMIA; ANGIOGENESIS; APOPTOSIS; BLOOD BRAIN BARRIER; BLOOD TRANSFUSION; CONCENTRATION (PARAMETERS); CRITICALLY ILL PATIENT; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG USE; ERYTHROCYTE LIFESPAN; ERYTHROCYTE TRANSFUSION; ERYTHROID CELL; HEART MUSCLE ISCHEMIA; HEMATOCRIT; HUMAN; HYPOXIA; INFECTION; INFLAMMATION; INTENSIVE CARE UNIT; IRON BLOOD LEVEL; IRON METABOLISM; IRON THERAPY; MORTALITY; MULTIPLE ORGAN FAILURE; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PERITONITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETICULOCYTE; REVIEW; SEPSIS;

ANEMIA; CRITICAL CARE; DRUG THERAPY, COMBINATION; ERYTHROPOIETIN; HEMATINICS; HUMANS; INTENSIVE CARE UNITS; IRON; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84862554200     PISSN: 07490704     EISSN: 15578232     Source Type: Journal    
DOI: 10.1016/j.ccc.2012.04.003     Document Type: Review

References (77)

1. Nutritional anemias: report of a WHO Scientific Group 1968, WHO Scientific Group on Nutritional Anemias, World Health Organization, Geneva (Switzerland), Accessed April 30, 2012. http://whqlibdoc.who.int/trs/WHO_TRS_405.pdf.
2. Guralnik J.M., Eisenstaedt R.S., Ferrucci L., et al. Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia. Blood 2004, 104:2263-2268.
3. Vincent J.L., Baron J.F., Reinhart K., et al. Anemia and blood transfusion in critically ill patients. JAMA 2002, 288:1499-1507.
4. Corwin H.L., Gettinger A., Pearl R.G., et al. The CRIT Study: anemia and blood transfusion in the critically ill--current clinical practice in the United States. Crit Care Med 2004, 32:39-52.
5. Walsh T.S., Garrioch M., Maciver C., et al. Red cell requirements for intensive care units adhering to evidence-based transfusion guidelines. Transfusion 2004, 44:1405-1411.
6. Carson J.L., Poses R.M., Spence R.K., et al. Severity of anaemia and operative mortality and morbidity. Lancet 1988, 1:727-729.
7. Mudumbai S.C., Cronkite R., Hu K.U., et al. Association of admission hematocrit with 6-month and 1-year mortality in intensive care unit patients. Transfusion 2011, 51:2148-2159.
8. Bateman A.P., McArdle F., Walsh T.S. Time course of anemia during six months follow up following intensive care discharge and factors associated with impaired recovery of erythropoiesis. Crit Care Med 2009, 37:1906-1912.
9. Nguyen B.V., Bota D.P., Melot C., et al. Time course of hemoglobin concentrations in nonbleeding intensive care unit patients. Crit Care Med 2003, 31:406-410.
10. Vincent J.L., Piagnerelli M. Transfusion in the intensive care unit. Crit Care Med 2006, 34:S96-S101.
11. Corwin H.L., Parsonnet K.C., Gettinger A. RBC transfusion in the ICU. Is there a reason?. Chest 1995, 108:767-771.
12. Hebert P.C., Wells G., Tweeddale M., et al. Does transfusion practice affect mortality in critically ill patients?. Transfusion Requirements in Critical Care (TRICC) Investigators and the Canadian Critical Care Trials Group. Am J Respir Crit Care Med 1997, 155:1618-1623.
13. Hebert P.C., Wells G., Blajchman M.A., et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 1999, 340:409-417.
14. Hebert P.C., Fergusson D.A., Stather D., et al. Revisiting transfusion practices in critically ill patients. Crit Care Med 2005, 33:7-12.
15. Netzer G., Liu X., Harris A.D., et al. Transfusion practice in the intensive care unit: a 10-year analysis. Transfusion 2010, 50:2125-2134.
16. Carson J.L., Terrin M.L., Noveck H., et al. Liberal or restrictive transfusion in high-risk patients after hip surgery. N Engl J Med 2011, 365:2453-2462.
17. Westbrook A., Pettila V., Nichol A., et al. Transfusion practice and guidelines in Australian and New Zealand intensive care units. Intensive Care Med 2010, 36:1138-1146.
18. Scharte M., Fink M.P. Red blood cell physiology in critical illness. Crit Care Med 2003, 31:S651-S657.
19. Kemna E., Pickkers P., Nemeth E., et al. Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS. Blood 2005, 106:1864-1866.
20. Theurl I., Theurl M., Seifert M., et al. Autocrine formation of hepcidin induces iron retention in human monocytes. Blood 2008, 111:2392-2399.
21. Theurl I., Aigner E., Theurl M., et al. Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: diagnostic and therapeutic implications. Blood 2009, 113:5277-5286.
22. Piagnerelli M., Vincent J.L. Role of iron in anaemic critically ill patients: it's time to investigate!. Crit Care 2004, 8:306-307.
23. Weiss G., Goodnough L.T. Anemia of chronic disease. N Engl J Med 2005, 352:1011-1023.
24. Munoz M., Romero A., Morales M., et al. Iron metabolism, inflammation and anemia in critically ill patients. A cross-sectional study. Nutr Hosp 2005, 20:115-120.
25. Patteril M.V., Davey-Quinn A.P., Gedney J.A., et al. Functional iron deficiency, infection and systemic inflammatory response syndrome in critical illness. Anaesth Intensive Care 2001, 29:473-478.
26. Bobbio-Pallavicini F., Verde G., Spriano P., et al. Body iron status in critically ill patients: significance of serum ferritin. Intensive Care Med 1989, 15:171-178.
27. Piagnerelli M., Rapotec A., Cotton F., et al. Iron administration in the critically ill. Semin Hematol 2006, 43(Suppl):S23-S27.
28. Mumby S., Margarson M., Quinlan G.J., et al. Is bleomycin-detectable iron present in the plasma of patients with septic shock?. Intensive Care Med 1997, 23:635-639.
29. Ozment C.P., Turi J.L. Iron overload following red blood cell transfusion and its impact on disease severity. Biochim Biophys Acta 2009, 1790:694-701.
30. Hod E.A., Zhang N., Sokol S.A., et al. Transfusion of red blood cells after prolonged storage produces harmful effects that are mediated by iron and inflammation. Blood 2010, 115:4284-4292.
31. Piagnerelli M., Cotton F., Herpain A., et al. Time course of iron metabolism in critically ill patients. Acta Clinica Belgica 2012, [Epub ahead of print.].
32. Rodriguez R.M., Corwin H.L., Gettinger A., et al. Nutritional deficiencies and blunted erythropoietin response as causes of the anemia of critical illness. J Crit Care 2001, 16:36-41.
33. Pieracci F.M., Barie P.S. Diagnosis and management of iron-related anemias in critical illness. Crit Care Med 2006, 34:1898-1905.
34. Fernandez R., Tubau I., Masip J., et al. Low reticulocyte hemoglobin content is associated with a higher blood transfusion rate in critically ill patients: a cohort study. Anesthesiology 2010, 112:1211-1215.
35. Lasocki S., Longrois D., Montravers P., et al. Hepcidin and anemia of the critically ill patient: bench to bedside. Anesthesiology 2011, 114:688-694.
36. Lasocki S., Millot S., Andrieu V., et al. Phlebotomies or erythropoietin injections allow mobilization of iron stores in a mouse model mimicking intensive care anemia. Crit Care Med 2008, 36:2388-2394.
37. Javadi P., Buchman T.G., Stromberg P.E., et al. High-dose exogenous iron following cecal ligation and puncture increases mortality rate in mice and is associated with an increase in gut epithelial and splenic apoptosis. Crit Care Med 2004, 32:1178-1185.
38. Hod E.A., Brittenham G.M., Billote G.B., et al. Transfusion of human volunteers with older, stored red blood cells produces extravascular hemolysis and circulating non-transferrin-bound iron. Blood 2011, 118:6675-6682.
39. Brasseur A., Cotton F., Zouaoui K., et al. Effects of red blood cell transfusion on iron metabolism and oxidative stress in critically ill patients [abstract]. Transfus Alt Transfus Med 2010, 11(Suppl 2):P21.
40. Agarwal R. Nonhematological benefits of iron. Am J Nephrol 2007, 27:565-571.
41. van Iperen C.E., Gaillard C.A., Kraaijenhagen R.J., et al. Response of erythropoiesis and iron metabolism to recombinant human erythropoietin in intensive care unit patients. Crit Care Med 2000, 28:2773-2778.
42. Vincent J.L., Spapen H.D., Creteur J., et al. Pharmacokinetics and pharmacodynamics of once-weekly subcutaneous epoetin alfa in critically ill patients: results of a randomized, double-blind, placebo-controlled trial. Crit Care Med 2006, 34:1661-1667.
43. Pieracci F.M., Henderson P., Rodney J.R., et al. Randomized, double-blind, placebo-controlled trial of effects of enteral iron supplementation on anemia and risk of infection during surgical critical illness. Surg Infect (Larchmt) 2009, 10:9-19.
44. Rogiers P., Zhang H., Leeman M., et al. Erythropoietin response is blunted in critically ill patients. Intensive Care Med 1997, 23:159-162.
45. Elliot J.M., Virankabutra T., Jones S., et al. Erythropoietin mimics the acute phase response in critical illness. Crit Care 2003, 7:R35-R40.
46. Vialet R., Ventre C., Leone M., et al. Erythropoietin measurements in severely traumatized patients. Acta Anaesthesiol Scand 2008, 52:601-604.
47. Claessens Y.E., Fontenay M., Pene F., et al. Erythropoiesis abnormalities contribute to early-onset anemia in patients with septic shock. Am J Respir Crit Care Med 2006, 174:51-57.
48. Still J.M., Belcher K., Law E.J., et al. A double-blinded prospective evaluation of recombinant human erythropoietin in acutely burned patients. J Trauma 1995, 38:233-236.
49. Gabriel A., Kozek S., Chiari A., et al. High-dose recombinant human erythropoietin stimulates reticulocyte production in patients with multiple organ dysfunction syndrome. J Trauma 1998, 44:361-367.
50. Corwin H.L., Gettinger A., Rodriguez R.M., et al. Efficacy of recombinant human erythropoietin in the critically ill patient: a randomized, double-blind, placebo-controlled trial. Crit Care Med 1999, 27:2346-2350.
51. Corwin H.L., Gettinger A., Pearl R.G., et al. Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial. JAMA 2002, 288:2827-2835.
52. Georgopoulos D., Matamis D., Routsi C., et al. Recombinant human erythropoietin therapy in critically ill patients: a dose-response study [ISRCTN48523317]. Crit Care 2005, 9:R508-R515.
53. Silver M., Corwin M.J., Bazan A., et al. Efficacy of recombinant human erythropoietin in critically ill patients admitted to a long-term acute care facility: a randomized, double-blind, placebo-controlled trial. Crit Care Med 2006, 34:2310-2316.
54. Corwin H.L., Gettinger A., Fabian T.C., et al. Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med 2007, 357:965-976.
55. Talving P., Lustenberger T., Kobayashi L., et al. Erythropoiesis stimulating agent administration improves survival after severe traumatic brain injury: a matched case control study. Ann Surg 2010, 251:1-4.
56. Arroliga A.C., Guntupalli K.K., Beaver J.S., et al. Pharmacokinetics and pharmacodynamics of six epoetin alfa dosing regimens in anemic critically ill patients without acute blood loss. Crit Care Med 2009, 37:1299-1307.
57. Brophy G.M., Sheehan V., Shapiro M.J., et al. A US multicenter, retrospective, observational study of erythropoiesis-stimulating agent utilization in anemic, critically ill patients admitted to the intensive care unit. Clin Ther 2008, 30:2324-2334.
58. Napolitano L.M., Fabian T.C., Kelly K.M., et al. Improved survival of critically ill trauma patients treated with recombinant human erythropoietin. J Trauma 2008, 65:285-297.
59. Zarychanski R., Turgeon A.F., McIntyre L., et al. Erythropoietin-receptor agonists in critically ill patients: a meta-analysis of randomized controlled trials. CMAJ 2007, 177:725-734.
60. Casadevall N., Nataf J., Viron B., et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002, 346:469-475.
61. Patel N.S., Collino M., Yaqoob M.M., et al. Erythropoietin in the intensive care unit: beyond treatment of anemia. Ann Intensive Care 2011, 1:40.
62. Arcasoy M.O. The non-haematopoietic biological effects of erythropoietin. Br J Haematol 2008, 141:14-31.
63. Walden A.P., Young J.D., Sharples E. Bench to bedside: a role for erythropoietin in sepsis. Crit Care 2010, 14:227.
64. Maiese K., Li F., Chong Z.Z. New avenues of exploration for erythropoietin. JAMA 2005, 293:90-95.
65. Sepodes B., Maio R., Pinto R., et al. Recombinant human erythropoietin protects the liver from hepatic ischemia-reperfusion injury in the rat. Transpl Int 2006, 19:919-926.
66. Siren A.L., Knerlich F., Poser W., et al. Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain. Acta Neuropathol 2001, 101:271-276.
67. Brines M.L., Ghezzi P., Keenan S., et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci U S A 2000, 97:10526-10531.
68. Ehrenreich H., Hasselblatt M., Dembowski C., et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 2002, 8:495-505.
69. Ehrenreich H., Weissenborn K., Prange H., et al. Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke 2009, 40:e647-e656.
70. Xenocostas A., Hu H., Chin-Yee N., et al. Erythropoietin is equally effective as fresh-blood transfusion at reducing infarct size in anemic rats. Crit Care Med 2010, 38:2215-2221.
71. Voors A.A., Belonje A.M., Zijlstra F., et al. A single dose of erythropoietin in ST-elevation myocardial infarction. Eur Heart J 2010, 31:2593-2600.
72. Najjar S.S., Rao S.V., Melloni C., et al. Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial. JAMA 2011, 305:1863-1872.
73. Ott I., Schulz S., Mehilli J., et al. Erythropoietin in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomized, double-blind trial. Circ Cardiovasc Interv 2010, 3:408-413.
74. Kao R., Xenocostas A., Rui T., et al. Erythropoietin improves skeletal muscle microcirculation and tissue bioenergetics in a mouse sepsis model. Crit Care 2007, 11:R58.
75. Kao R.L., Martin C.M., Xenocostas A., et al. Erythropoietin improves skeletal muscle microcirculation through the activation of eNOS in a mouse sepsis model. J Trauma 2011, 71:S462-S467.
76. Cuzzocrea S., Di P.R., Mazzon E., et al. Erythropoietin reduces the development of nonseptic shock induced by zymosan in mice. Crit Care Med 2006, 34:1168-1177.
77. Mitra A., Bansal S., Wang W., et al. Erythropoietin ameliorates renal dysfunction during endotoxaemia. Nephrol Dial Transplant 2007, 22:2349-2353.